Mode
Text Size
Log in / Sign up

PD-L1 and CTLA-4 Variants Linked to Genitourinary Cancer RiskGenetic variations linked to risk of certain genitourinary cancers

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
PD-L1 rs4143815 may lower urothelial cancer risk, while CTLA-4 rs5742909 may raise GU cancer risk in Asian populations.

A meta-analysis of 16 case-control studies examined whether single-nucleotide polymorphisms (SNPs) in immune checkpoint genes PD-1, PD-L1, and CTLA-4 are associated with susceptibility to genitourinary (GU) cancers, including urothelial carcinoma, renal cell carcinoma, and prostate cancer.

The analysis found that PD-L1 rs4143815 was associated with a significantly decreased risk of urothelial carcinoma in Asian populations under the dominant model (OR 0.34, 95% CI 0.14-0.87). In contrast, CTLA-4 rs5742909 was associated with increased risk of GU cancer overall in both dominant (OR 1.41, 95% CI 1.11-1.80) and allele (OR 1.34, 95% CI 1.05-1.72) models. For urothelial carcinoma specifically in Asian populations, CTLA-4 rs5742909 also showed increased risk in the dominant model (OR 1.56, 95% CI 1.04-2.34).

No data were reported on safety outcomes, follow-up duration, or study setting. Limitations and funding sources were not described in the abstract.

These findings identify specific polymorphisms in PD-L1 and CTLA-4 that are associated with susceptibility to GU cancer in Asian populations. However, the results reflect associations only and do not establish causation. Further research is needed to confirm these relationships and understand their clinical implications.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the genetic drivers of genitourinary cancers. While prior coverage noted that biomarker-driven strategies and genomic classifiers may improve risk stratification in prostate cancer, this study specifically identifies SNPs in PD-1, PD-L1, and CTLA-4 associated with susceptibility to urothelial, renal cell, and prostate cancers.

When we look at why some people develop certain cancers while others do not, genetics often play a hidden role. New research looked at how specific genetic variations, known as single-nucleotide polymorphisms (SNPs), might influence a person's risk of developing genitourinary cancers, which include bladder, kidney, and prostate cancers.

The study analyzed 16 cases to see how these genetic markers behaved. They found that a specific variation in the PD-L1 gene was linked to a lower risk of bladder cancer in Asian populations. On the other hand, a different variation in the CTLA-4 gene was linked to a higher risk of both general genitourinary cancers and specifically bladder cancer in Asian populations.

It is important to remember that these findings show an association, not a direct cause. This means that while these genetic markers are linked to risk levels, they do not guarantee a diagnosis. Because the data is based on specific genetic markers, the results may vary depending on a person's unique genetic makeup.

What this means for you:
Specific genetic variations in PD-L1 and CTLA-4 genes are linked to different risks for bladder and kidney cancers.

Common questions

What specific genes were linked to cancer risk?

The study looked at variations in two specific genes: PD-L1 and CTLA-4. These are genes involved in the immune system. Specifically, the research found that variations in the PD-L1 gene (rs4143815) and the CTLA-4 gene (rs5742909) were linked to different risk levels for genitourinary cancers like bladder and kidney cancer.

How did the risk change based on these genes?

The results were mixed depending on the gene. A variation in the PD-L1 gene was linked to a significantly lower risk of bladder cancer in Asian populations. However, a variation in the CTLA-4 gene was linked to an increased risk of both general genitourinary cancers and bladder cancer in Asian populations.

Does having these genetic markers mean I will get cancer?

No, these findings show an association, not a direct cause. This means the study found a link between certain genetic markers and cancer risk, but it does not mean that having these markers will definitely cause cancer. You should speak with a doctor to understand what these findings mean for your personal health.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
This meta-analysis explored the association of immune checkpoint-related single-nucleotide polymorphisms (SNPs) in programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) genes with susceptibility to various genitourinary (GU) cancers, including urothelial carcinoma (UC), renal cell carcinoma (RCC), and prostate cancer (PCa). PubMed, Embase, Cochrane Library, and Web of Science were searched for case-control studies from inception to April 2026. Six SNPs, including PD-1 (rs2227981), PD-L1 (rs4143815), and CTLA-4 (rs3087243, rs231775, rs5742909, and rs11571302), were examined. The relationships between the SNPs and cancer susceptibility were evaluated using pooled odds ratios (ORs) and 95% confidence intervals (CIs) for dominant, recessive, and allele models. This study considered 16 case-control studies. PD-L1 rs4143815 was associated with a significantly decreased risk of UC in Asian populations under the dominant model (CC + CG vs. GG: OR = 0.34, 95% CI = 0.14-0.87). CTLA-4 rs5742909 polymorphism was associated with an increased risk of GU cancer in dominant model (TT + TC vs. CC: OR = 1.41, 95% CI = 1.11-1.80) and allele model (T vs. C: OR = 1.34, 95% CI = 1.05-1.72). A significantly increased risk of UC was further identified among Asian population in the dominant model (OR = 1.56, 95% CI = 1.04-2.34). No significant associations were observed for the other SNPs. In conclusion, specific polymorphisms in immune checkpoint-related genes, particularly PD-L1 rs4143815 and CTLA-4 rs5742909, are associated with susceptibility to GU cancer in Asian populations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.